Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02119650 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT02119650 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 76 participants.
The verdict
NCT02119650, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.
Interventions
- DRUG Placebo
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2014-02-11 |
| Est. Completion | 2016-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02119650
The ClinicalTrials.gov registry entry for NCT02119650 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02119650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02119650 about?
NCT02119650 is a clinical study titled "Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer". The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.
What is the current status of trial NCT02119650?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2014-02-11. Estimated completion is 2016-06-21.
What interventions are being tested in trial NCT02119650?
The interventions under investigation include: Placebo (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT02119650?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.